---
document_datetime: 2026-01-23 16:35:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aranesp-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aranesp-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.917358
conversion_datetime: 2026-01-26 20:48:33.878846
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aranesp

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| Variation type II /  | C.I.11 Introduction of, or change(s) to, the | 27/11/2025                          |                                             | Annex II and                     | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000267359                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted - - Accepted Submission of an updated RMP version 10.0 in order to remove the safety concern and risk minimisation measures regarding the 'Incorrect Use of the Pre-filled Pen Device Associated with Adverse Reactions, Including Underdose and Drug Dose Omission'. The   |            |     | PL   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000281362 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of                                                                                                                             | 09/10/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------|